• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Design of Inhibitors of Influenza Virus Membrane Fusion: Synthesis, Structure-Activity Relationship and in vitro Antiviral Activity of a Novel Indole

tetano

Editor, Senior Moderator
Antiviral Res. 2013 May 21. pii: S0166-3542(13)00136-8. doi: 10.1016/j.antiviral.2013.05.005. [Epub ahead of print]
Design of Inhibitors of Influenza Virus Membrane Fusion: Synthesis, Structure-Activity Relationship and in vitro Antiviral Activity of a Novel Indole Series.
Brancato V, Peduto A, Wharton S, Martin S, More V, Mola AD, Massa A, Perfetto B, Donnarumma G, Schiraldi C, Tufano MA, de Rosa M, Filosa R, Hay A.
Source

MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK; Department of Experimental Medicine, Microbiology and Clinical Microbiology Section, Faculty of Medicine and Surgery, Second University of Naples, Naples, Italy; Present address: Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, P. Le Tecchio 80, 80125 Naples, Italy.
Abstract

The fusion of virus and endosome membranes is an essential early stage in influenza virus infection. The low pH-induced conformational change which promotes the fusogenic activity of the haemagglutinin (HA) is thus an attractive target as an antiviral strategy. The anti-influenza drug Arbidol is representative of a class of antivirals which inhibits HA-mediated membrane fusion by increasing the acid stability of the HA. In this study two series of indole derivatives structurally related to Arbidol were designed and synthesized to further probe the foundation of its antiviral activity and develop the basis for a structure-activity relationship (SAR). Ethyl 5-(hydroxymethyl)-1-methyl-2-(phenysulphanylmethyl)-1H-indole-3-carboxylate (15) was identified as one of the most potent inhibitors and more potent than Arbidol against certain subtypes of influenza A viruses. In particular, 15 exhibited a much greater affinity and preference for binding group 2 than group 1 HAs, and exerted a greater stabilising effect, in contrast to Arbidol. The results provide the basis for more detailed SAR studies of Arbidol binding to HA; however, the greater affinity for binding HA was not reflected in a comparable increase in antiviral activity of 15, apparently reflecting the complex nature of the antiviral activity of Arbidol and its derivatives.

Copyright ? 2013. Published by Elsevier B.V.

PMID:
23707194
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23707194
 
Back
Top Bottom